Regencell Bioscience Holdings Ltd
RGC- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001829667
No open-market purchases or sales by Regencell Bioscience Holdings Ltd insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $8.56M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Regencell Bioscience Holdings Ltd changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 2 | 5 | +3 |
| Shares | 7.01K | 20.3K | +13.2K (+189.0%) |
| Value | $230.0K | $434.0K | +$204.0K (+88.7%) |
New holders (4)
Institutions that held Regencell Bioscience Holdings Ltd at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Qube Research & Technologies Ltd | 17,329 | $371.0K | 0.00% |
| Citigroup Inc | 2,240 | $48.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 432 | $10.0K | 0.00% |
| Morgan Stanley | 6 | $0 | 0.00% |
Sold out (1)
Institutions that held Regencell Bioscience Holdings Ltd at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Geode Capital Management, LLC | 6,816 | $224.0K |